 SOUTH SAN FRANCISCO, Calif., April 14, 2021 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody technology platform, today announced that on April 1, 2021, the Company granted a new employee an option to purchase a total of 120,000 shares of the Companys common stock at an exercise price per share equal to 7.87, which was the closing trading price on April 1, 2021, the date of the grant. In addition, on April 12, 2021, the Company also granted another new employee an option to purchase a total of 275,000 shares of the Companys common stock at an exercise price per share equal to 6.74, which was the closing trading price on April 12, 2021, the date of the grant. 